RESUMO
Novel nonpeptide small molecule renin inhibitors bearing an N-isopropyl P(1) motif were designed based on initial lead structures 1 and aliskiren (2). (P(3)-P(1))-Benzamide derivatives such as 9a and 34, as well as the corresponding P(1) basic tertiary amine derivatives 10 and 35 were found to display low nanomolar inhibition against human renin in vitro.
Assuntos
Amidas/química , Anti-Hipertensivos/química , Benzamidas/química , Etilenos/química , Fumaratos/química , Inibidores de Proteases/química , Renina/antagonistas & inibidores , Administração Oral , Animais , Anti-Hipertensivos/síntese química , Anti-Hipertensivos/farmacologia , Benzamidas/síntese química , Benzamidas/farmacologia , Callithrix , Humanos , Inibidores de Proteases/síntese química , Inibidores de Proteases/farmacologia , Renina/metabolismo , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
The action of renin is the rate-limiting step of the renin-angiotensin system (RAS), a key regulator of blood pressure. Effective renin inhibitors directly block the RAS entirely at source and, thus, may provide a vital weapon for hypertension therapy. Our efforts toward identifying novel small-molecule peptidomimetic renin inhibitors have resulted in the design of transition-state isosteres such as 1 bearing an all-carbon 8-phenyl-octanecarboxamide framework. Optimization of the extended P3 portion of 1 and extensive P2' modifications provided analogues with improved in vitro potencies in the presence of plasma. X-ray resolution of rh-renin/38a in the course of SAR work surprisingly unveiled the exploitation of a previously unexplored pocket (S3sp) important for strong binding affinities. Several inhibitors demonstrated oral efficacy in sodium-depleted marmosets. The most potent, 38a, induced dose-dependently a pronounced reduction in mean arterial blood pressure, paralleled by complete blockade of active plasma renin, up to 8 h post-dose. Oral bioavailability of 38a was 16% in marmosets.
Assuntos
Amidas/síntese química , Anisóis/síntese química , Anti-Hipertensivos/síntese química , Caprilatos/síntese química , Peptídeos/química , Renina/antagonistas & inibidores , Administração Oral , Amidas/química , Amidas/farmacologia , Animais , Anisóis/química , Anisóis/farmacologia , Anti-Hipertensivos/química , Anti-Hipertensivos/farmacologia , Disponibilidade Biológica , Pressão Sanguínea/efeitos dos fármacos , Callithrix , Caprilatos/química , Caprilatos/farmacologia , Cristalografia por Raios X , Frequência Cardíaca/efeitos dos fármacos , Humanos , Cinética , Modelos Moleculares , Mimetismo Molecular , Estrutura Molecular , Ligação Proteica , Renina/sangue , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Due to its function in the rate limiting initial step of the renin-angiotensin system, renin is a particularly promising target for drugs designed to control hypertension, a growing risk to health worldwide. Despite vast efforts over more than two decades, no orally efficacious renin inhibitor had reached the market. As a result of a structure-based topological design approach, we have identified a novel class of small-molecule inhibitors with good oral blood-pressure lowering effects in primates. Further lead optimization aimed for improvement of in vivo potency and duration of action, mainly by P2' modifications at the hydroxyethylene transition-state isostere. These efforts resulted in the discovery of aliskiren (46, CGP060536B, SPP100), a highly potent, selective inhibitor of renin, demonstrating excellent efficacy in sodium-depleted marmosets after oral administration, with sustained duration of action in reducing dose-dependently mean arterial blood pressure. Aliskiren has recently received regulatory approval by the U.S. Food and Drug Administration for the treatment of hypertension.
Assuntos
Amidas/síntese química , Anti-Hipertensivos/síntese química , Caprilatos/síntese química , Fumaratos/síntese química , Renina/antagonistas & inibidores , Administração Oral , Amidas/química , Amidas/farmacologia , Animais , Anti-Hipertensivos/química , Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Callithrix , Caprilatos/química , Caprilatos/farmacologia , Cristalografia por Raios X , Fumaratos/química , Fumaratos/farmacologia , Frequência Cardíaca/efeitos dos fármacos , Humanos , Cinética , Modelos Moleculares , Estrutura Molecular , Ligação Proteica , Renina/sangue , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
At Ciba-Geigy (now Novartis), the clinical development of the CGP38560 renin inhibitor was halted due to insufficient pharmacokinetics. This indicated that the peptidomimetic approach to the development of antihypertensive agents was improper. Real non-peptide drug candidates were then expected to provide the necessary framework for obtaining the desired properties. For this purpose a homology model of the enzyme was used to characterize the binding mode of CGP38560 in complex with the renin model and served as a basis for the four chemistry laboratories that were assigned to this project. The renin team worked in a full structure-based perspective with this model, and four chemically-unrelated non-peptide series were discovered acting as renin inhibitors at the 1-3 nanomolar level. One of these leads was selected for further development and led to Aliskiren, which has been just approved by the FDA. Here is presented the successful structure-based strategy that enabled the discovery of several non-peptide inhibitors and the recent launch of a new drug that will be commercialized in the United States under the name Tekturna (for the treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications).
Assuntos
Amidas/química , Materiais Biomiméticos/química , Desenho de Fármacos , Inibidores Enzimáticos/química , Fumaratos/química , Modelos Moleculares , Renina/antagonistas & inibidores , Amidas/farmacocinética , Amidas/uso terapêutico , Animais , Materiais Biomiméticos/farmacocinética , Materiais Biomiméticos/uso terapêutico , Aprovação de Drogas , Inibidores Enzimáticos/farmacocinética , Inibidores Enzimáticos/uso terapêutico , Fumaratos/farmacocinética , Fumaratos/uso terapêutico , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/enzimologia , Relação Estrutura-Atividade , Estados Unidos , United States Food and Drug AdministrationRESUMO
Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial infarction, and heart failure, the leading causes of death in the Western world. Inhibitors of the renin-angiotensin system (RAS) have proven to be successful treatments for hypertension. As renin specifically catalyses the rate-limiting step of the RAS, it represents the optimal target for RAS inhibition. Several peptide-like renin inhibitors have been synthesized previously, but poor pharmacokinetic properties meant that these compounds were not clinically useful. We employed a combination of molecular modelling and crystallographic structure analysis to design renin inhibitors lacking the extended peptide-like backbone of earlier inhibitors, for improved pharmacokinetic properties. This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients. Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.